Core Viewpoint - Daily Journal Corporation is addressing allegations from Buxton Helmsley USA, Inc. regarding improper accounting practices related to software development costs, asserting that it has complied with accounting standards [1][2]. Group 1: Allegations and Responses - Buxton Helmsley USA, Inc. claims that Daily Journal Corporation should capitalize its software development costs instead of expensing them, suggesting this change would unlock shareholder value [2]. - The Audit Committee of Daily Journal Corporation reviewed the allegations and confirmed that the company is correctly accounting for its software development costs in accordance with ASC 950-20 [3]. Group 2: Accounting Standards Explanation - Historically, software companies followed ASC 985-20, which allows capitalization of development costs only after technological feasibility is established and before general release [4]. - The evolution of software development practices, particularly the adoption of agile methodologies, has shortened the capitalization window, making it rare for companies to incur significant costs eligible for capitalization [6]. - Companies developing software as a service (SaaS) may capitalize costs under ASC 350-40, which has a longer development window compared to ASC 985-20 [7]. Group 3: Misunderstandings and Clarifications - Buxton Helmsley USA, Inc. appears to have misunderstood the accounting practices of other companies, as they likely use different standards for capitalizing costs [8]. - Daily Journal Corporation emphasizes that it will continue to expense development costs when appropriate and capitalize them when justified, ensuring transparency in reporting R&D costs [9]. Group 4: Call for Resolution - Daily Journal Corporation urges Mr. Parker to cease his unfounded attacks and allow the company to focus on creating actual business value for shareholders [11].

Core Insights - Mill City Ventures III, Ltd. has established itself as the largest publicly traded SUI treasury, backed by an exclusive relationship with the Sui Foundation, and aims to provide institutional-grade access to the SUI blockchain [2][7] - The company has scaled its total treasury holdings to approximately 81.9 million SUI as of August 10, 2025, and is currently staking all SUI in the treasury, earning about $26,000 per day [7][8] - Mill City reported a 64% increase in net assets resulting from operations for Q2 2025, amounting to approximately $677,000, or $0.11 per share, compared to $413,000, or $0.06 per share in Q2 2024 [10] Company Developments - The company launched the first publicly traded, Foundation-backed SUI treasury strategy on July 31, 2025, focusing on acquiring SUI tokens through various channels [1][2] - Mill City has raised $450 million in capital through a PIPE offering as of August 1, 2025, with Galaxy appointed as Asset Management to manage the SUI treasury [7][10] - The company plans to continue its existing commercial short-term non-bank lending and specialty finance business while executing its SUI treasury strategy [1][8] Industry Context - SUI is positioned as a next-generation Layer 1 blockchain designed for scalability, speed, and security, enabling decentralized applications across various sectors including finance and gaming [3][4] - The Sui Foundation is dedicated to the advancement and adoption of the SUI network, providing Mill City with insights and access to strategic network growth initiatives [2][7] - The architecture of SUI is designed to support mass market consumer applications in Web3, potentially transforming the global economy [4][6]

Core Viewpoint - Orca Energy Group Inc. reported its Q2 2025 financial results, highlighting operational performance, revenue changes, and ongoing legal disputes affecting its operations in Tanzania [1][2][3]. Financial Performance - Revenue decreased by 3% for Q2 2025 and by 1% for the six months ended June 30, 2025, primarily due to increased revenue share for the Tanzanian Petroleum Development Corporation (TPDC) [3][6]. - Net income attributable to shareholders increased by 1,786% for Q2 2025 and by 943% for the six months ended June 30, 2025, mainly due to the reversal of loss allowance following the collection of long-term arrears from TANESCO [4][6]. - Net cash flows from operating activities increased by 91% for Q2 2025 and by 394% for the six months ended June 30, 2025, attributed to higher payments from TANESCO [4][6]. Operational Highlights - Daily gas sold increased by 9% for Q2 2025 compared to Q2 2024, driven by robust demand from industrial customers, with sales growing over 40% from H1 2024 [2][6]. - Gas deliveries increased by 9% for Q2 2025 and by 2% for the six months ended June 30, 2025, influenced by higher consumption from industrial customers and the end of the Protected Gas regime [3][6]. Capital Expenditures - Capital expenditures decreased by 98% for Q2 2025 and by 82% for the six months ended June 30, 2025, primarily due to deferred projects and inclement weather affecting operations [4][6]. Legal and Regulatory Matters - The company is involved in arbitration proceedings initiated by PAEM and PAET against the Government of Tanzania for breaches of investment agreements [3][4]. - A settlement agreement was signed with TANESCO for $52 million regarding unpaid amounts, with TANESCO having paid $34.1 million to date [4][6]. Working Capital and Cash Position - As of June 30, 2025, the company reported working capital of approximately $49.3 million and cash and cash equivalents of approximately $98.6 million [4][6].

Core Insights - Appili Therapeutics has submitted a total of seven U.S. government funding proposals, with a potential combined award value of up to US$137 million, aimed at advancing infectious disease and biodefense products [3][4][6] - The company has been accepted as a member of the U.S. Medical CBRN Defense Consortium, enhancing its partnerships in government and biodefense sectors [4][5] - Financial results for the first quarter of fiscal 2026 show a net loss of $1.2 million, a decrease from $1.6 million in the same period last year, attributed to reduced financing costs and lower research and development expenses [16] Funding Proposals - Appili has submitted seven non-dilutive funding proposals to U.S. government agencies, which include submissions to the Congressionally Directed Medical Research Program, the U.S. Medical CBRN Defense Consortium, and the National Institute of Allergy and Infectious Diseases [3][4] - If awarded, these funds will support the development of projects through manufacturing, non-clinical development, and regulatory activities necessary for IND submissions and Phase 1 clinical trials [3] Biodefense Initiatives - The company is advancing its live-attenuated vaccine candidate, ATI-1701, for the prevention of tularemia, with approximately US$11.6 million in funding from the U.S. Air Force Academy [6][7] - Recent data published indicates that ATI-1701 provides robust protection against lethal tularemia in non-human primates, supporting its potential as a leading vaccine candidate [7] Product Development - LIKMEZ, a metronidazole oral suspension, has been re-launched in the U.S. and is the first FDA-approved ready-to-use liquid formulation for patients who have difficulty swallowing tablets [10][11] - The company is also advancing ATI-1801, a topical formulation for cutaneous leishmaniasis, with positive Phase 3 data and ongoing efforts to secure non-dilutive funding for its development [12][14] Financial Overview - For the three months ended June 30, 2025, the company reported a net loss of $1.2 million, reflecting a decrease in financing costs and research and development expenses [16] - As of June 30, 2025, the company had cash reserves of $1.1 million, a slight decrease from $1.2 million at the end of the previous quarter [16]

Core Insights - Maui Land & Pineapple Company, Inc. reported strong financial performance with a 103% increase in operating revenues for the first half of 2025 compared to the same period in 2024, totaling $10,406,000 [3][9] - The company is focusing on maximizing land productivity and diversifying revenue streams, including launching an agave venture and improving leasing revenues, which increased by 46% year-over-year [2][3] Financial Performance - Operating revenues for the six months ended June 30, 2025, were $10,406,000, up from $5,128,000 in the same period in 2024, marking an increase of $5,278,000 [3][9] - Land development and sales revenues rose to $3,442,000 from $200,000, primarily due to contracting revenues from the Honokeana Homes Relief Housing Project [3][9] - Leasing revenues increased to $6,421,000 from $4,388,000, attributed to improved occupancy and updated leases [3][9] Costs and Expenses - Total operating costs and expenses for the first half of 2025 were $12,897,000, compared to $8,409,000 in 2024, an increase of $4,488,000 [3][9] - The increase in operating costs was mainly due to land development and sales costs of $3,157,000 related to the Honokeana Homes project [3][9] - Water and conservation costs rose to $1,253,000 from $709,000, reflecting increased operations and maintenance costs [3][9] Net Loss and Adjusted EBITDA - The net GAAP loss for the first half of 2025 was ($9,639,000), or ($0.49) per share, compared to a loss of ($3,247,000) or ($0.16) per share in 2024 [3][9] - Adjusted EBITDA for the six months ended June 30, 2025, was ($192,000), an improvement of $55,000 from ($247,000) in the same period in 2024 [3][9] Cash and Investments - Cash and Investments Convertible to Cash totaled $7,028,000 on June 30, 2025, down from $9,522,000 at the end of 2024, primarily due to pension termination contributions and development expenditures [3][9]

Core Viewpoint - The merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc. is a transformative step aimed at creating a vertically integrated company that enhances growth, efficiency, and long-term value creation [2]. Company Overview - Regional Health Properties, Inc. is a self-managed healthcare real estate investment company focused on investing in real estate for senior living and long-term care [7]. Merger Details - The merger was completed on August 14, 2025, with Regional surviving as the merged entity [1]. - Each five shares of SunLink common stock were converted into 1.1330 shares of Regional common stock and one share of Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares [3]. - The total consideration for the merger included approximately 1,595,400 shares of Regional common stock and approximately 1,408,120 shares of Regional Series D preferred stock [3]. Leadership Structure - The combined company will be led by Brent S. Morrison as President and CEO, with Mark J. Stockslager as CFO and Robert M. Thornton, Jr. as Executive Vice President – Corporate Strategy [5]. - The Board of Directors will include members from both Regional and SunLink, ensuring continuity and integration of leadership [6]. Trading Information - The combined company will operate under the name Regional Health Properties, Inc. and will continue to trade under Regional's ticker symbols on the OTCQB [4].

MISSISSAUGA, Ontario, Aug. 14, 2025 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months and six months ended June 30, 2025 on Thursday, August 21, 2025 after market hours. A presentation on the Company’s second quarter and first half 2025 results by René Goehrum, BioSyent President and CEO, will also be available on the Company’s website on the date of release. About BioSyent Inc. Listed on the TSX Venture Exchange under ...

Financial Performance - Quarterly net revenues reached RMB 706.4 million (US$ 98.6 million), representing a year-over-year increase of 53.9% from RMB 458.9 million [6][9] - Quarterly net income was RMB 44.1 million (US$ 6.2 million), a significant improvement compared to a net loss of RMB 72.1 million in the same period last year [2][9] - For the first six months of 2025, total shipments surpassed those of the entire year of 2024, with net income reaching RMB 26.5 million (US$ 3.7 million) [2][9] Business Growth and Market Position - The second quarter saw a surge in growth momentum, with net revenues increasing over 50% year-over-year, driven by strong customer demand and operational execution [2] - The company secured numerous design wins for 20 models from 9 leading OEMs, including a platform win for multiple 2026 models with a top ADAS customer [2][3] - In the Robotics sector, the company ranked No. 1 in lidar shipments in China for the first half of 2025, indicating strong market leadership [2][7] Product and Technology Development - The company achieved the C-sample milestone for its long-range lidar sensor with a top European OEM, confirming product maturity and successful testing [3] - The long-range lidar debuted at the 2025 Shanghai Auto Show, showcasing its application in high-profile vehicles such as SAIC Audi's sports car and Cadillac VISTIQ SUV [3] - The company is positioned to capitalize on the growing demand for lidar technology in both automotive and robotics applications, leveraging its expertise and global scale [2][7] Operational Highlights - Total lidar shipments for the second quarter were 352,095 units, a remarkable increase of 306.9% from 86,526 units in the same period of 2024 [8] - ADAS lidar shipments reached 303,564 units, representing a 275.8% increase from 80,773 units in the corresponding period of 2024 [8] - The company reported a gross margin of 42.5% for the second quarter, slightly down from 45.1% in the same period last year, primarily due to a decrease in high-margin service revenues [9]

Millicom (Tigo) Reaches Strategic Agreement with EPM to facilitate Merger Process with ColTel Luxembourg, August 14, 2025 – Millicom (Tigo) today announced a key agreement with Empresas Públicas de Medellín (EPM) that advances its acquisition strategy in Colombia and unlocks a path toward the integration of Tigo-UNE and Colombia Telecomunicaciones (ColTel). Under the terms of the agreement: Millicom has committed to present an offer in EPM’s Law 226 sale process, subject to the terms published by EPM on Jul ...

Company Overview - Rein Therapeutics is a clinical-stage biopharmaceutical company focused on developing first-in-class therapies for orphan pulmonary and fibrosis indications [3] - The lead product candidate, LTI-03, is a synthetic peptide targeting alveolar epithelial cell survival and inhibiting profibrotic signaling, currently in clinical development [3] - The second product candidate, LTI-01, has completed Phase 1b and Phase 2a trials for loculated pleural effusions and has received Orphan Drug Designation in both the U.S. and E.U. [3] Upcoming Events - Chief Scientific Officer Cory Hogaboam will present at the IPF Summit 2025 on August 19-21, 2025, discussing the role of immune cells and inflammation in idiopathic pulmonary fibrosis (IPF) [2] - CEO Brian Windsor will present on August 21, focusing on innovative clinical trial design and lessons learned from the LTI-03 trial [2] Research and Development Focus - The presentations will cover the modulation of lung-resident macrophages and the potential of Caveolin-scaffolding domain (CSD) peptides in targeting multiple drivers of fibrosis [5] - Rein's Phase 2 trial of LTI-03 aims to enroll up to 120 patients, assessing safety, tolerability, and lung function as key outcomes [5] - The company is strategizing around patient recruitment and trial design to ensure relevance in a rapidly evolving treatment landscape [5]